読み込み中
MeiraGTx Holdings plc operates as a clinical-stage gene therapy company, dedicated to pioneering therapeutic solutions for individuals afflicted by serious illnesses. Its development efforts span a broad spectrum of conditions, encompassing ocular diseases like inherited forms of blindness, as well as xerostomia (dry mouth) that often follows radiation treatment for head and neck cancers. The company also targets various degenerative and neurodegenerative disorders, notably amyotrophic lateral sclerosis (ALS) and Parkinson's disease. Currently, several of its programs are in active clinical development, including Phase 1/2 trials for Achromatopsia, X-Linked Retinitis Pigmentosa, RPE65-deficiency, radiation-induced Xerostomia, and Parkinson's. MeiraGTx is also preparing to commence a clinical program for xerostomia linked to Sjogren's syndrome and maintains preclinical initiatives for other neurodegenerative conditions. A key collaboration exists with Janssen Pharmaceuticals, Inc. to advance regulatable gene therapy treatments, leveraging MeiraGTx's proprietary riboswitch technology. Established in 2015, MeiraGTx Holdings plc is headquartered in New York, New York.
前日終値
$10.69
+$0.19 · +1.81%
日中の時刻はETです。市場データは遅延する場合があります。
MeiraGTx Holdings plc operates as a clinical-stage gene therapy company, dedicated to pioneering therapeutic solutions for individuals afflicted by serious illnesses. Its development efforts span a broad spectrum of conditions, encompassing ocular diseases like inherited forms of blindness, as well as xerostomia (dry mouth) that often follows radiation treatment for head and neck cancers. The company also targets various degenerative and neurodegenerative disorders, notably amyotrophic lateral sclerosis (ALS) and Parkinson's disease. Currently, several of its programs are in active clinical development, including Phase 1/2 trials for Achromatopsia, X-Linked Retinitis Pigmentosa, RPE65-deficiency, radiation-induced Xerostomia, and Parkinson's. MeiraGTx is also preparing to commence a clinical program for xerostomia linked to Sjogren's syndrome and maintains preclinical initiatives for other neurodegenerative conditions. A key collaboration exists with Janssen Pharmaceuticals, Inc. to advance regulatable gene therapy treatments, leveraging MeiraGTx's proprietary riboswitch technology. Established in 2015, MeiraGTx Holdings plc is headquartered in New York, New York.
日中レンジ
現在 $10.69
52週レンジ
現在 $10.69
日中の時刻はETです。市場データは遅延する場合があります。
GoAI スコア
中立
バリュエーション
62
割安
センチメント
65
強気
リスク
49
やや高いリスク
モメンタム
70
上昇基調
GoAIの詳細リサーチ
詳しい根拠、カタリスト、リスクを確認できます。
MeiraGTx Holdings plc operates as a clinical-stage gene therapy company, dedicated to pioneering therapeutic solutions for individuals afflicted by serious illnesses. Its development efforts span a broad spectrum of conditions, encompassing ocular diseases like inherited forms of blindness, as well as xerostomia (dry mouth) that often follows radiation treatment for head and neck cancers. The company also targets various degenerative and neurodegenerative disorders, notably amyotrophic lateral sclerosis (ALS) and Parkinson's disease. Currently, several of its programs are in active clinical development, including Phase 1/2 trials for Achromatopsia, X-Linked Retinitis Pigmentosa, RPE65-deficiency, radiation-induced Xerostomia, and Parkinson's. MeiraGTx is also preparing to commence a clinical program for xerostomia linked to Sjogren's syndrome and maintains preclinical initiatives for other neurodegenerative conditions. A key collaboration exists with Janssen Pharmaceuticals, Inc. to advance regulatable gene therapy treatments, leveraging MeiraGTx's proprietary riboswitch technology. Established in 2015, MeiraGTx Holdings plc is headquartered in New York, New York.
日中レンジ
現在 $10.69
52週レンジ
現在 $10.69
利用可能な期間全体で報告されたマージン。
売上高
営業利益
純利益
| 指標（USD） | 2025年度 | 2024年度 | 2023年度 | 2022年度 | 2021年度 |
|---|---|---|---|---|---|
| 売上高 | 8139.1万 USD | 3327.9万 USD | 1401.7万 USD | 1592万 USD | 3770.1万 USD |
| 売上原価 | 484.3万 USD | 2379.1万 USD | — | — | — |
| 粗利益 | 7654.8万 USD | 948.8万 USD | 1401.7万 USD | 1592万 USD | 3770.1万 USD |
| 研究開発 | 1.3億 USD | 1.19億 USD | 1.04億 USD | 8572.5万 USD | 6669.4万 USD |
| 販売・一般管理 | 5289.7万 USD | 5421.6万 USD | 4729.3万 USD | 4655万 USD | 4376.5万 USD |
| 営業費用 | 1.83億 USD | 1.74億 USD | 1.51億 USD | 1.32億 USD | 1.1億 USD |
| 受取利息 | 181.8万 USD | 414.5万 USD | 227.2万 USD | 77.7万 USD | 21.2万 USD |
| 支払利息 | 1219.7万 USD | 1327.2万 USD | 1324.5万 USD | 494.6万 USD | 28.8万 USD |
| 減価償却費と償却費 | 1254.2万 USD | 1282.8万 USD | 1372.4万 USD | 860.3万 USD | 787.3万 USD |
| 営業利益 | −1.06億 USD | −1.64億 USD | −1.37億 USD | −1.16億 USD | −7275.8万 USD |
| 純利益 | −1.14億 USD | −1.48億 USD | −8402.7万 USD | −1.3億 USD | −7956.1万 USD |
会社概要が更新されました 2026年10月11日.
直近の発表実績
直近の発表実績
第三者のアナリスト予想は変更される場合があり、GoAIの推奨ではありません。
平均目標
$21.00
上昇余地（96.45%）この株式へのエクスポージャーを報告している上場投資信託です。
iShares Russell 2000 ETFIWM1647.98万0.02%787.4億 USD0.19%$278.94+0.49%
First Trust Small Cap Growth AlphaDEX FundFYC664.94万0.49%13.49億 USD0.70%$115.36+1.35%
iShares Biotechnology ETFIBB592.55万0.06%108.2億 USD0.44%$206.49+3.00%
Vanguard Russell 2000 ETFVTWO477.41万0.03%180億 USD0.06%$112.66+0.50%
iShares Russell 2000 Growth ETFIWO456.12万0.03%139.17億 USD0.24%$356.78+0.94%
State Street SPDR S&P Kensho New Economies Composite ETFKOMP272.5万0.10%26.06億 USD0.20%$66.35+1.13%
First Trust Small Cap Core AlphaDEX FundFYX244.81万0.18%13.4億 USD0.58%$135.38+0.28%
Janus Henderson Small Cap Growth Alpha ETFJSML244.19万0.68%3.61億 USD0.30%$87.477+1.00%iShares Russell 2000 ETFIWMFirst Trust Small Cap Growth AlphaDEX FundFYCiShares Biotechnology ETFIBBVanguard Russell 2000 ETFVTWOiShares Russell 2000 Growth ETFIWOState Street SPDR S&P Kensho New Economies Composite ETFKOMPFirst Trust Small Cap Core AlphaDEX FundFYXJanus Henderson Small Cap Growth Alpha ETFJSMLAIが生成した遅延市場データを、情報提供および教育目的で掲載しています。投資助言ではありません。
